PriceTargets.com logo

NASDAQ:SYBX - Synlogic Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.60
  • Forecasted Upside: 282.84 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.03 As of 09/28/2021 01:23 PM ET
▼ -0.02 (-0.66%)

This chart shows the closing price for SYBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Synlogic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYBX

Analyst Price Target is $11.60
▲ +282.84% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Synlogic in the last 3 months. The average price target is $11.60, with a high forecast of $15.00 and a low forecast of $9.00. The average price target represents a 282.84% upside from the last price of $3.03.

This chart shows the closing price for SYBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Synlogic. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/6/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/20/2021Piper SandlerBoost Price TargetOverweight$7.00 ➝ $9.00High
9/7/2021HC WainwrightReiterated RatingBuy$9.00Low
7/15/2021HC WainwrightSet Price TargetBuy$3.26Medium
7/9/2021Chardan CapitalInitiated CoverageBuy$10.00Medium
6/28/2021HC WainwrightLower Price TargetBuy$13.00 ➝ $9.00Low
5/18/2021SVB LeerinkReiterated RatingBuy$15.00Low
5/14/2021OppenheimerReiterated RatingHoldMedium
3/25/2021SVB LeerinkBoost Price TargetOutperform$10.00 ➝ $15.00Low
3/18/2021JonestradingInitiated CoverageBuy$15.00High
1/13/2021Chardan CapitalBoost Price TargetBuy$5.00 ➝ $10.00High
9/18/2020Chardan CapitalReiterated RatingBuy$5.00Medium
8/10/2020HC WainwrightReiterated RatingBuyHigh
5/22/2020HC WainwrightReiterated RatingBuy$13.00N/A
5/10/2020OppenheimerReiterated RatingHoldMedium
3/23/2020HC WainwrightReiterated RatingBuy$13.00Low
3/12/2020OppenheimerReiterated RatingHoldHigh
1/13/2020HC WainwrightReiterated RatingBuy$13.00High
12/11/2019HC WainwrightReiterated RatingBuy$13.00Medium
11/13/2019Piper Jaffray CompaniesReiterated RatingOverweight$10.00 ➝ $7.00High
9/19/2019Chardan CapitalReiterated RatingBuyHigh
9/9/2019HC WainwrightReiterated RatingBuy$13.00High
9/4/2019Piper Jaffray CompaniesSet Price TargetBuy$10.00Low
8/21/2019HC WainwrightLower Price TargetBuy$22.00 ➝ $13.00Medium
8/21/2019CitigroupDowngradeBuy ➝ Sell$20.00 ➝ $2.00High
8/20/2019OppenheimerDowngradeOutperform ➝ Market PerformHigh
8/20/2019Piper Jaffray CompaniesReiterated RatingOverweight$10.00 ➝ $20.00High
8/12/2019HC WainwrightReiterated RatingBuy$22.00High
8/9/2019WedbushReiterated RatingOutperform$20.00Low
7/16/2019HC WainwrightBoost Price TargetBuy$20.00 ➝ $22.00High
7/15/2019Chardan CapitalSet Price TargetBuy$25.00High
7/15/2019Piper Jaffray CompaniesBoost Price TargetOverweight$16.00 ➝ $20.00Low
6/24/2019HC WainwrightReiterated RatingBuy$20.00Low
6/12/2019WedbushReiterated RatingOutperform$20.00High
6/12/2019Piper Jaffray CompaniesBoost Price TargetOverweight$15.00 ➝ $16.00High
4/30/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$18.00High
4/12/2019Chardan CapitalSet Price TargetBuy$20.00Medium
3/12/2019Chardan CapitalReiterated RatingBuy$20.00High
2/12/2019BTIG ResearchInitiated CoverageBuy$22.00 ➝ $22.00High
12/13/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$20.00Medium
12/10/2018HC WainwrightSet Price TargetBuy$20.00High
11/13/2018HC WainwrightReiterated RatingBuy$20.00Low
11/12/2018OppenheimerSet Price TargetBuy$18.00High
10/9/2018HC WainwrightSet Price TargetBuy$20.00Low
9/7/2018WedbushReiterated RatingOutperformLow
9/5/2018CitigroupBoost Price TargetBuy$26.00High
8/24/2018CitigroupUpgradeNeutral ➝ BuyHigh
8/9/2018HC WainwrightSet Price TargetBuy$20.00High
6/29/2018OppenheimerInitiated CoverageOutperform$18.00High
6/11/2018HC WainwrightReiterated RatingBuy$20.00High
5/22/2018HC WainwrightSet Price TargetBuy$20.00Low
5/11/2018HC WainwrightSet Price TargetBuy$20.00High
4/17/2018HC WainwrightReiterated RatingBuy$20.00High
4/9/2018Piper Jaffray CompaniesReiterated RatingBuy$15.00Low
4/4/2018HC WainwrightSet Price TargetBuy$20.00Low
3/19/2018HC WainwrightInitiated CoverageBuy ➝ Buy$20.00Low
1/29/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$16.00High
11/27/2017WedbushInitiated CoverageOutperform$20.00Medium
9/19/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$25.00Low
4/13/2017Cantor FitzgeraldReiterated RatingHold$14.00Low
11/15/2016HC WainwrightReiterated RatingHoldN/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
7/30/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2021
  • 4 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2021

Current Sentiment

  • 4 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Synlogic logo
Synlogic, Inc. engages in the discovery and development of Synthetic Biotic medicines. It focuses in Phenylketonuria, Enteric Hyperoxaluria, Immuno Oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $3.03
Low: $2.96
High: $3.03

50 Day Range

MA: $3.00
Low: $2.45
High: $3.71

52 Week Range

Now: $3.03
Low: $1.78
High: $5.11

Volume

8,177 shs

Average Volume

672,722 shs

Market Capitalization

$158.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Synlogic?

The following Wall Street sell-side analysts have issued research reports on Synlogic in the last year: Chardan Capital, HC Wainwright, Jonestrading, Oppenheimer Holdings Inc., Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for SYBX.

What is the current price target for Synlogic?

5 Wall Street analysts have set twelve-month price targets for Synlogic in the last year. Their average twelve-month price target is $11.60, suggesting a possible upside of 282.8%. SVB Leerink LLC has the highest price target set, predicting SYBX will reach $15.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $9.00 for Synlogic in the next year.
View the latest price targets for SYBX.

What is the current consensus analyst rating for Synlogic?

Synlogic currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYBX will outperform the market and that investors should add to their positions of Synlogic.
View the latest ratings for SYBX.

How do I contact Synlogic's investor relations team?

Synlogic's physical mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company's listed phone number is (617) 401-9975 and its investor relations email address is [email protected] The official website for Synlogic is www.synlogictx.com.